Is a 503B compounding pharmacy FDA-approved?

503B facilities operate under Section 503B of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013. They register with FDA, are inspected on a risk-based schedule, and must comply with current Good Manufacturing Practice (cGMP) regulations. They may compound from bulk drug substances on FDA's positive list and sell to hospitals and clinics without patient-specific prescriptions.

The compounded products themselves are not subject to the New Drug Application (NDA) approval process that applies to commercial drug products. This is a substantive regulatory distinction: an NDA-approved drug carries an FDA finding of safety and efficacy for the labeled indication; a 503B compounded preparation carries no such finding, only cGMP compliance for its production.

Hospital purchase contracts often reference "FDA-approved" products. Hospitals using 503B preparations have made a conscious decision to source compounded products and need contract language that accommodates the 503B regulatory category - and the operator's insurance schedule needs to satisfy the hospital schedule for compounded products specifically, not for NDA-approved manufactured drugs.

For sponsor MSAs where a 503B is acting as a compounding partner for a clinical or commercial product, the indemnity and insurance clauses need to be drafted with awareness of the 503B regulatory category. Many template sponsor MSAs assume the supplier holds an NDA and contain language that does not map cleanly to a 503B relationship.